Anava A Wren1, Rachel Bensen1, Lindsay Sceats2, Melody Dehghan1, Helen Yu1, Jessie J Wong3,4, Donna MacIsaac1,2, Zachary M Sellers1, Cindy Kin2, K T Park1. 1. Stanford Children's Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Pediatrics, Stanford, California. 2. Division of Colorectal Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, California. 3. Center for Primary Care and Outcomes Research, Stanford, California. 4. Center for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, California.
Abstract
Background: Opioids are commonly prescribed for relief in inflammatory bowel disease (IBD). Emerging evidence suggests that adolescents and young adults are a vulnerable population at particular risk of becoming chronic opioid users and experiencing adverse effects. Objectives: This study evaluates trends in the prevalence and persistence of chronic opioid therapy in adolescents and young adults with IBD in the United States. Method: A longitudinal retrospective cohort analysis was conducted with the Truven MarketScan Database from 2007 to 2015. Study subjects were 15-29 years old with ≥2 IBD diagnoses (Crohn's: 555/K50; ulcerative colitis: 556/K51). Opioid therapy was identified with prescription claims within the Truven therapeutic class 60: opioid agonists. Persistence of opioid use was evaluated by survival analysis for patients who remained in the database for at least 3 years following index chronic opioid therapy use. Results: In a cohort containing 93,668 patients, 18.2% received chronic opioid therapy. The annual prevalence of chronic opioid therapy increased from 9.3% in 2007 to 10.8% in 2015 (P < 0.01), peaking at 12.2% in 2011. Opioid prescriptions per patient per year were stable (approximately 5). Post hoc Poisson regression analyses demonstrated that the number of opioid pills dispensed per year increased with age and was higher among males. Among the 2503 patients receiving chronic opioid therapy and followed longitudinally, 30.5% were maintained on chronic opioid therapy for 2 years, and 5.3% for all 4 years. Conclusion: Sustained chronic opioid use in adolescents and young adults with IBD is increasingly common, underscoring the need for screening and intervention for this vulnerable population.
Background: Opioids are commonly prescribed for relief in inflammatory bowel disease (IBD). Emerging evidence suggests that adolescents and young adults are a vulnerable population at particular risk of becoming chronic opioid users and experiencing adverse effects. Objectives: This study evaluates trends in the prevalence and persistence of chronic opioid therapy in adolescents and young adults with IBD in the United States. Method: A longitudinal retrospective cohort analysis was conducted with the Truven MarketScan Database from 2007 to 2015. Study subjects were 15-29 years old with ≥2 IBD diagnoses (Crohn's: 555/K50; ulcerative colitis: 556/K51). Opioid therapy was identified with prescription claims within the Truven therapeutic class 60: opioid agonists. Persistence of opioid use was evaluated by survival analysis for patients who remained in the database for at least 3 years following index chronic opioid therapy use. Results: In a cohort containing 93,668 patients, 18.2% received chronic opioid therapy. The annual prevalence of chronic opioid therapy increased from 9.3% in 2007 to 10.8% in 2015 (P < 0.01), peaking at 12.2% in 2011. Opioid prescriptions per patient per year were stable (approximately 5). Post hoc Poisson regression analyses demonstrated that the number of opioid pills dispensed per year increased with age and was higher among males. Among the 2503 patients receiving chronic opioid therapy and followed longitudinally, 30.5% were maintained on chronic opioid therapy for 2 years, and 5.3% for all 4 years. Conclusion: Sustained chronic opioid use in adolescents and young adults with IBD is increasingly common, underscoring the need for screening and intervention for this vulnerable population.
Authors: Karen A Hanson; Edward V Loftus; W Scott Harmsen; Nancy N Diehl; Alan R Zinsmeister; William J Sandborn Journal: Inflamm Bowel Dis Date: 2009-05 Impact factor: 5.325
Authors: Gary R Lichtenstein; Brian G Feagan; Russell D Cohen; Bruce A Salzberg; Robert H Diamond; Donny M Chen; Michelle L Pritchard; William J Sandborn Journal: Clin Gastroenterol Hepatol Date: 2006-05 Impact factor: 11.382
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: David M S Grunkemeier; Joseph E Cassara; Christine B Dalton; Douglas A Drossman Journal: Clin Gastroenterol Hepatol Date: 2007-10 Impact factor: 11.382
Authors: Tonya M Palermo; Christopher Eccleston; Amy S Lewandowski; Amanda C de C Williams; Stephen Morley Journal: Pain Date: 2009-11-11 Impact factor: 6.961
Authors: Mohamed Noureldin; Peter D R Higgins; Shail M Govani; Shirley Cohen-Mekelburg; Brooke C Kenney; Ryan W Stidham; Jennifer F Waljee; Akbar K Waljee Journal: Aliment Pharmacol Ther Date: 2018-11-14 Impact factor: 8.171
Authors: Anava A Wren; Nicole Neiman; Thomas J Caruso; Samuel Rodriguez; Katherine Taylor; Martine Madill; Hal Rives; Linda Nguyen Journal: Children (Basel) Date: 2021-05-05
Authors: Andry Van de Louw; Eric Mariotte; Michael Darmon; Austin Cohrs; Douglas Leslie; Elie Azoulay Journal: PLoS One Date: 2021-08-12 Impact factor: 3.240